anaxirone has been researched along with Thrombocytopenia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clavel, M; Decoster, G; Holdener, EE; Klepp, O; Ludwig, C; Pinedo, HM; Renard, G; Sessa, C; Siegenthaler, P; ten Bokkel Huinink, W | 1 |
| Benshahar, D; Capellaere, P; Kerbrat, P; Rouëssé, JG; Thomas, D; van Coninge, CJ; van Oosterom, AT | 1 |
| Crespeigne, N; Decoster, G; Dodion, P; Gerard, B; Kenis, Y; Lambert, M; Nicaise, C; Rozencweig, M | 1 |
| Bruntsch, U; Dodion, P; Hansen, HH; Hansen, M; Pinedo, HM; Renard, J; Ten Bokkel Huinink, WW; Van Glabbeke, M | 1 |
| Bach, F; Cavalli, F; Hansen, HH; Hansen, SW; Kaplan, S | 1 |
1 trial(s) available for anaxirone and Thrombocytopenia
| Article | Year |
|---|---|
Phase II trial of anaxirone (TGU) in advanced colorectal cancer: an EORTC Early Clinical Trials Group (ECTG) study.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Thrombocytopenia; Treatment Outcome; Triazoles | 1994 |
4 other study(ies) available for anaxirone and Thrombocytopenia
| Article | Year |
|---|---|
Phase II study of 1,2,4-triglycidyl urasol (TGU) in advanced soft tissue sarcoma. A trial of the EORTC Soft Tissue and Bone Sarcoma Cooperative Group.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Thrombocytopenia; Triazoles | 1987 |
Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Injections, Intravenous; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia; Triazoles | 1986 |
Primary resistance of renal adenocarcinoma to 1,2,4-triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent--a phase II study of the EORTC early clinical trials group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Kidney Neoplasms; Leukopenia; Male; Middle Aged; Thrombocytopenia; Triazoles | 1986 |
Phase I trial of 1,2,4-triglycidylurazol (TGU, NSC 332488): a new triepoxide cytostatic agent.
Topics: Adult; Aged; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Phlebitis; Thrombocytopenia; Triazoles | 1985 |